Prostate Cancer in the United States

1for prostate cancer is relatively good, with 5.8 % of cancer deaths in men being attributed to prostate cancer (Parkin et al., 2005). Prostate cancer has a 5-year disease-specific survival of 56.6 % and overall survival of 38 % (National Cancer Registry Ireland, 2004). Low Gleason scores, clinical staging, and tumor aggressiveness on diagnosis predict increased survival in men with prostate cancer. Improved avail-ability of global transportation and communication has afforded the health care community the unprece-dented opportunity to understand the most current worldwide knowledge regarding diseases such as prostate cancer. Consequently, health care providers have the opportunity to learn about the health con-cerns of other countries with similar problems. A description of uncertainty and quality of life (QOL) among men with prostate cancer in samples from Prostate cancer continues to be the most com-mon site of male cancers, particularly amongolder men in Europe and the United States, and the second most common male cancer world-wide (Parkin, Bray, Ferlay, & Pisani, 2005). Prostate cancer accounts for approximately 21 % of all male cancers and 7 % of cancer deaths in Ireland (Nationa